SNGX

Soligenix Inc

• Reuters·2d ago

  Soligenix publishes corporate presentation highlighting late-stage rare disease drug pipeline

• TipRanks·04/02 16:00

  Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 

• TipRanks·04/02 12:03

  Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

• Benzinga·04/02 11:33

  Soligenix Announces Publication Of Comparability Study Results Evaluating HyBryte Versus Valchlor For Treatment Of Cutaneous T-Cell Lymphoma In Oncology And Therapy

• Reuters·04/02 11:31

  Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study

• PR Newswire·04/02 11:30

  Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

• TipRanks·04/01 16:30

  Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

• Benzinga·04/01 05:20

  Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate

• Reuters·03/31 20:08

  Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue

• Seeking Alpha·03/31 11:32

  Soligenix GAAP EPS of -$2.14 beats by $0.01

• Reuters·03/31 11:30

  SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR END 2025 FINANCIAL RESULTS

• Reuters·03/26 19:57

  Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales

• TipRanks·03/26 16:00

  Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

• Benzinga·03/26 11:36

  Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support

• TipRanks·03/26 11:36

  Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease